attyloid’s recent publication has outlined the establishment of an internal quality control (IQC) standard aimed at improving the robustness of attyloid’s surface-based Fluorescence Intensity Distribution Analysis (sFIDA) technology. Recognized for its high sensitivity and specificity, sFIDA is a leading technology used in studying protein aggregates, crucial in neurodegenerative diseases like Alzheimer’s and Parkinson’s.
The introduction of the IQC standard is expected to enhance both the reliability and standardization of the sFIDA assays. This advance will not only pave the way for more consistent results but also elevate the technology’s applicability in clinical diagnostics and research settings.
This publication serves as a milestone for attyloid’s sFIDA technology, emphasizing its commitment to quality assurance and pushing the boundaries in the field of neurodegenerative disease research.